These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8299367)

  • 1. Influence of glucocorticoid substances and the vehicle on skin irritancy: determination by profilometry.
    Korting HC
    Curr Probl Dermatol; 1993; 21():140-6. PubMed ID: 8299367
    [No Abstract]   [Full Text] [Related]  

  • 2. Topical glucocorticoids and thinning of normal skin as to be assessed by ultrasound.
    Korting HC
    Curr Probl Dermatol; 1993; 21():114-21. PubMed ID: 8299364
    [No Abstract]   [Full Text] [Related]  

  • 3. Side effects of topical glucocorticoids.
    Mills CM; Marks R
    Curr Probl Dermatol; 1993; 21():122-31. PubMed ID: 8299365
    [No Abstract]   [Full Text] [Related]  

  • 4. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
    Korting HC; Vieluf D; Kerscher M
    Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of glucocorticoid-specific epidermal alterations using skin surface microscopy.
    Schulz H; Nietsch KH; Höhler T
    Curr Probl Dermatol; 1993; 21():132-9. PubMed ID: 8299366
    [No Abstract]   [Full Text] [Related]  

  • 6. Local tolerability of topically applied methylprednisolone aceponate.
    Kecskés A; Jahn P; Lange L
    J Am Acad Dermatol; 1993 May; 28(5 Pt 1):786-8. PubMed ID: 8496430
    [No Abstract]   [Full Text] [Related]  

  • 7. Response of segmental vitiligo to 0.05% clobetasol propionate cream.
    Khalid M; Mujtaba G
    Int J Dermatol; 1998 Sep; 37(9):705-8. PubMed ID: 9762827
    [No Abstract]   [Full Text] [Related]  

  • 8. In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle.
    Gans EH; Sadiq I; Stoudemayer T; Stoudemayer M; Kligman AM
    J Drugs Dermatol; 2008 Jan; 7(1):28-32. PubMed ID: 18246695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis.
    Kerscher MJ; Korting HC
    Skin Pharmacol; 1992; 5(2):77-80. PubMed ID: 1637562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
    Serup J; Holm P
    Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpigmenting solitary fixed drug eruption after skin testing and intra-articular injection of triamcinolone acetonide.
    Sener O; Caliskaner Z; Yazicioglu K; Karaayvaz M; Ozangüç N
    Ann Allergy Asthma Immunol; 2001 Mar; 86(3):335-6. PubMed ID: 11289335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
    Cossmann M; Welzel J
    Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
    J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 0.05% clobetasol propionate cream and topical Puvasol in childhood vitiligo.
    Khalid M; Mujtaba G; Haroon TS
    Int J Dermatol; 1995 Mar; 34(3):203-5. PubMed ID: 7751099
    [No Abstract]   [Full Text] [Related]  

  • 15. Suppression of induced inflammation in man.
    Kerscher MJ
    Curr Probl Dermatol; 1993; 21():97-106. PubMed ID: 8299382
    [No Abstract]   [Full Text] [Related]  

  • 16. Cutaneous adverse reactions after intra-articular injection of triamcinolone acetonide.
    Ijsselmuiden OE; Knegt-Junk KJ; van Wijk RG; van Joost T
    Acta Derm Venereol; 1995 Jan; 75(1):57-8. PubMed ID: 7747537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis.
    Callender VD; Young CM; Haverstock CL; Carroll CL; Feldman SR
    Cutis; 2005 Jun; 75(6):317-21. PubMed ID: 16047868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis.
    Blum G; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1153-6. PubMed ID: 1757607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients preferences for different corticosteroid vehicles are highly variable.
    Felix K; Unrue E; Inyang M; Cardwell LA; Oussedik E; Richardson I; Feldman SR
    J Dermatolog Treat; 2020 Mar; 31(2):147-151. PubMed ID: 29770722
    [No Abstract]   [Full Text] [Related]  

  • 20. Different skin thinning potential of equipotent medium-strength glucocorticoids.
    Korting HC; Unholzer A; Schäfer-Korting M; Tausch I; Gassmueller J; Nietsch KH
    Skin Pharmacol Appl Skin Physiol; 2002; 15(2):85-91. PubMed ID: 11867964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.